公开(公告)号：US20230242486A1

公开(公告)日：2023-08-03

申请号：US18007840

申请日：2021-05-28

申请人： SHANGHAI ZHONGZE THERAPEUTICS, CO. LTD. ,  SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY

发明人： Jianqi LI ,  Yangli QI ,  Xiaowen CHEN ,  Junwei XU ,  Ruixiang YUAN ,  Qiang PU

IPC分类号： C07D213/74 ,  C07D213/87 ,  C07D401/04 ,  C07D405/14 ,  C07D405/12 ,  C07D405/04 ,  C07D409/04 ,  C07D409/14

CPC分类号： C07D213/74 ,  C07D213/87 ,  C07D401/04 ,  C07D405/14 ,  C07D405/12 ,  C07D405/04 ,  C07D409/04 ,  C07D409/14

摘要： Disclosed in the present invention are a pyridinyl morpholine compound, a preparation method therefor, and an application thereof. The present invention provides a pyridinyl morpholine compound as represented by formula I, a pharmaceutically acceptable salt thereof or a hydrate of the pharmaceutically acceptable salt thereof. The compound can be used as an antagonist for one or more of D2, D3 or 5-HT2A, and is used for preparing a drug for treating schizophrenia.